Healthline: What we know about Eli Lilly’s experimental weight-loss drug
UC expert says weight loss often doesn’t last long term
According to drugmaker Eli Lilly, participants in a clinical trial lost over 50 pounds on average when they were treated with the highest dose of a new hunger suppressant.
The drug, called tirzepatide, is making headlines, but has not yet been approved or authorized by the Food and Drug Administration. Additionally, the initial research has been made public by the drug maker Eli Lilly and has not yet been published in a peer-reviewed medical journal.
In a story on the drug published by Healthline, one of the experts quoted is Shailendra Patel, MD, PhD, Division of Endocrinology, Diabetes and Metabolism in the Department of Internal Medicine at the UC College of Medicine.
Shailendra Patel, MD, PhD, Division of Endocrinology, Diabetes and Metabolism at the UC College of Medicine/Photo/Colleen Kelley/UC Creative + Brand
Patel told Healthline that approaches to weight loss have typically involved dieting but that diets often result only in short term weight loss because they are extremely difficult to stick with for an indefinite period of time.
“The reason that all these diets fail is that human beings cannot stick with any one of these diet plans forever,” he said.
Patel points out that due to the complexity of obesity relying on a single solution, whether a diet or a pill, is likely not going to work long term.
“We have yet another weight loss drug to help patients," said Patel. “But drugs by themselves, just like crash diets by themselves, you can see weight loss – but you won’t be successful.”
He said if people with obesity want to lose weight it may require multiple interventions some of which may include medical interventions.
Patel pointed out that even bariatric surgery, which involves shrinking or bypassing the stomach through surgery, requires patients to change their long-term approach to diet and exercise for the best results.
Lead photo/Darron Cummings/AP
Impact Lives Here
The University of Cincinnati is leading public urban universities into a new era of innovation and impact. Our faculty, staff and students are saving lives, changing outcomes and bending the future in our city's direction. Next Lives Here.
Related Stories
University of Cincinnati gets $1.1M for AI physician training
January 30, 2026
The University of Cincinnati College of Medicine has received a four-year, $1.1 million grant to explore using artificial intelligence and personalized learning to improve physician education.
Hoxworth Blood Center teams up with Cyclones in February for biggest blood drive event of year
January 30, 2026
Hoxworth Blood Center, University of Cincinnati, is teaming up with the Cyclones and other local businesses to host its annual Queen City Blood Drive on Feb. 9-11 at Heritage Bank Center. If you can’t attend this event, Hoxworth encourages you to still make donating a #HoxworthHabit and give blood this February.
Research findings may lead to new test for endometriosis
January 30, 2026
Endometriosis affects one in 10 women worldwide, and many go years before diagnosis. Symptoms include chronic pelvic pain, heavy bleeding during menstruation and/or sexual intercourse, bloating and fatigue. Katie Burns’ research at the University of Cincinnati is focused on creating a new, non-invasive test for endometriosis, using white blood cells as biomarkers. Burns, PhD, is an associate professor in the Department of Environmental and Public Health Sciences in the College of Medicine.